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Objectives: Juvenile myositis is a rare and heterogeneous disease. Diagnosis is often difﬁcult but early
treatment is important in reducing the risk of associated morbidity and poor outcomes. Myositis speciﬁc
autoantibodies have been described in both juvenile and adult patients with myositis and can be helpful
in dividing patients into clinically homogenous groups. We aimed to explore the utility of myositis
speciﬁc autoantibodies as diagnostic and prognostic biomarkers in patients with juvenile-onset disease.
Methods: Using radio-labelled immunoprecipitation and previously validated ELISAs we examined the
presence of myositis speciﬁc autoantibodies in 380 patients with juvenile-onset myositis in addition to,
318 patients with juvenile idiopathic arthritis, 21 patients with juvenile-onset SLE, 27 patients with
muscular dystrophies, and 48 healthy children.
Results: An autoantibody was identiﬁed in 60% of juvenile-onset myositis patients. Myositis speciﬁc
autoantibodies (49% patients) were exclusively found in patients with myositis and with the exception of
one case were mutually exclusive and not found in conjunction with another autoantibody. Autoantibody
subtypes were associated with age at disease onset, key clinical disease features and treatment received.
Conclusions: In juvenile patients the identiﬁcation of a myositis speciﬁc autoantibody is highly sugges-
tive of myositis. Autoantibodies can be identiﬁed in the majority of affected children and provide useful
prognostic information. There is evidence of a differential treatment approach and patients with anti-
TIF1g autoantibodies are signiﬁcantly more likely to receive aggressive treatment with IV cyclophos-
phamide and/or biologic drugs, clear trends are also visible in other autoantibody subgroups.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).r Rheumatic Diseases, Upper
Ltd. This is an open access article
ey, et al., Autoantibodies in ju
utoimmunity (2017), http://1. Introduction
Juvenile-onset myositis refers to a group of rare childhood
autoimmune diseases that typically present with proximal muscleunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
venile-onset myositis: Their diagnostic value and associated clinical
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Abbreviations
JDCBS Juvenile Dermatomyositis Cohort and Biomarker
Study
CAPS Childhood Arthritis Prospective Cohort Study
CMAS Childhood Myositis Assessment Score
PGA Physician Global Assessment visual analogue score
Anti-TIF1g anti-transcription intermediary factor gamma
autoantibody
Anti-NXP2 anti-nuclear matrix protein 2 autoantibody
Anti-MDA5 anti-melanoma differentiation associated
protein 5 autoantibody
Anti-SRP anti-signal recognition peptide autoantibody
Anti-HMGCR anti-3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase autoantibody
Anti-SAE anti-small ubiquitin-like modiﬁer activating
enzyme autoantibody
Anti-PmScl anti-Polymyositis Scleroderma autoantibody
Anti-U1RNP anti-U1 Ribonucleoprotein autoantibody
MSA Myositis speciﬁc autoantibody
MAA Myositis associated autoantibody
S.L. Tansley et al. / Journal of Autoimmunity xxx (2017) 1e102weakness and elevated muscle enzymes; more than 90% of affected
children have associated skin disease and are thus classiﬁed as
Juvenile Dermatomyositis (JDM) [1]. Juvenile myositis is clinically
highly heterogeneous with muscle weakness ranging from pro-
found and requiring hospitalisation, to clinically amyopathic der-
matomyositis with normal muscle strength. Extra-muscular
disease including skin and internal organ involvement contributes
signiﬁcantly to disease morbidity. Patient sub-stratiﬁcation is
desirable to inform prognosis and guide further investigation and
treatment. Traditionally subgroups based on clinical and histo-
pathological criteria include polymyositis, dermatomyositis and
overlap syndromes but this classiﬁcation fails to explain all of the
variation in what is a complex disease and the boundaries between
traditional subgroups are becoming increasingly indistinct. Auto-
antibodies identiﬁable in patients withmyositis are often described
as either myositis speciﬁc (MSA) or myositis associated (MAA). MSA
are believed to occur exclusively in patients with an idiopathic in-
ﬂammatory myopathy while MAA may also occur in patients with
other connective tissue diseases or an overlap disorder. Collectively
autoantibodies have been identiﬁed in 60e70% of patients with
juvenile myositis and can divide patients into clinically homoge-
nous subgroups [2e6]. There is growing evidence for the utility of
autoantibodies as biomarkers to predict disease features and
outcome in juvenile myositis [2e8].
Despite well described pathognomonic features, the diagnosis
of juvenile myositis can be challenging; a recent study from North
America reported a median delay in diagnosis of 4e6 months [9].
The differential diagnosis of muscular weakness in children is wide
and additional features such as arthralgia or Raynaud's phenome-
non may lead to consideration of other more common childhood
rheumatological diseases such as juvenile idiopathic arthritis (JIA)
or juvenile-onset systemic lupus erythematosus (JSLE). The possi-
bility of overlap disorders compounds this problem. Furthermore,
the muscular dystrophies and other genetic muscle diseases are
important to exclude. It is crucial that diagnostic difﬁculties can be
overcome as early diagnosis and initiation of aggressive treatment
has been shown to reduce morbidity and improve patient outcome
[9e12]. Myositis speciﬁc autoantibodies are believed to occur
exclusively in patients with myositis and have not been found inPlease cite this article in press as: S.L. Tansley, et al., Autoantibodies in ju
phenotype in a large UK cohort, Journal of Autoimmunity (2017), http://patients with genetic muscle disease in the absence of a coexistent
inﬂammatory myopathy [13]. As standard testing for myositis
speciﬁc autoantibodies becomes more widely available, there is
growing interest in their use in diagnosis and predicting prognosis.
In this study we analyse the prevalence and clinical associations of
MSA/MAA in a large cohort of UK children with juvenile myositis
compared to healthy children and those suffering from diseases
with overlapping clinical features, JIA and JSLE.
2. Materials and methods
2.1. Patients with juvenile myositis
Patient serum samples and clinical data were available for 380
children enrolled in the UK Juvenile Dermatomyositis Cohort and
Biomarker Study (JDCBS). The JDCBS is a large cohort of UK patients
with myositis, the majority with JDM [1]. Patients are recruited
from paediatric rheumatology departments across the UK, and data
are collected prospectively on standardised proformas. Patients
aged 16 years are included based on a diagnosis of deﬁnite or
probable JDM or polymyositis by Bohan and Peter criteria [14]; as
well as JDM or polymyositis with overlap connective tissue disease
features. The JDCBS was established in 2001 and many patients
have more than 15 years of follow-up data available. The median
length of time from symptom onset to time of analysis of patients
included in this study was 9.31 years.
We investigated the presence or absence of key disease features
occurring at any point over the follow-up period including calci-
nosis, dysphagia, cutaneous ulceration, lipoatrophy and arthritis.
The lowest ever recorded childhood myositis assessment score
(CMAS) was used as a measure of the maximum recorded muscle
weakness: CMAS is a systematic and validated measure of muscle
strength in children with juvenile myositis. The score ranges be-
tween 0 and 52, with lower scores corresponding to a greater de-
gree of clinical weakness [15]. We used the highest ever recorded
physician global assessment visual analogue score (PGA) as a proxy
measure for maximal disease activity/severity. PGA graded 0e10, is
used as an overall measure of disease activity, a higher score
reﬂecting more active disease.
In the UK ﬁrst line treatment for juvenile-onset myositis is
typically methotrexate with cortico-steroids, a regime recently
been shown in an international randomised trial, to be optimal
compared to steroids alone [16]. Strict guidelines exist for the
administration of biologic drugs and these are reserved for the
most unwell patients, who have failed to respond to ﬁrst-line
medications. We determined whether patients had at any point
received treatment with any biologic drug and/or intravenous
cyclophosphamide.
2.2. Patients with JIA
Patient serum samples were obtained for 318 children enrolled
in the Childhood Arthritis Prospective Study (CAPS), a prospective
longitudinal inception cohort study of children with new onset
inﬂammatory arthritis [17]. Patients are recruited from 7 tertiary
referral centres across the UK. Children aged 16 years with newly
diagnosed inﬂammatory arthritis in one or more joints, which had
persisted for at least 2 weeks, are invited to participate. Exclusion
criteria include septic arthritis, haemarthrosis, arthritis caused by
malignancy or trauma and connective tissue disease.
2.3. Patients with JSLE
Patient serum samples were obtained for 21 children enrolled in
the UK Juvenile Systemic Lupus Erythematosus (JSLE) Cohort Studyvenile-onset myositis: Their diagnostic value and associated clinical
dx.doi.org/10.1016/j.jaut.2017.06.007
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aged 16 years are recruited from centres across the UK. All JSLE
samples included here were collected from patients being cared for
in the Department of Paediatric Rheumatology, Alder Hey Chil-
dren's NHS Foundation Trust. The data collection and repository has
previously been described [18].
2.4. Muscular dystrophy
Patient serum samples were obtained from 27 children with
muscular dystrophies (20 Duchene muscular dystrophy, 5 Becker
muscular dystrophy and 2 Limb girdle type 2Dmuscular dystrophy)
through the Medical Research Centre for Neuromuscular Disorders
Biobank at University College London.
2.5. Healthy controls
Serum was obtained from 48 healthy subjects aged 16 years
attending Alder Hey Children's NHS Foundation Trust, Liverpool,
UK for elective surgery where no intercurrent infection or family
history of autoimmune disease was present, as part of the UK JSLE
Cohort Study (see above).
For all studies ethical approval has been obtained and parental
consent for children, and consent or age-appropriate assent was
obtained for all patients in accordance with the declaration of
Helsinki.
2.6. Myositis speciﬁc autoantibody detection
Immunoprecipitation of radiolabelled K562 cells was performed
on all samples to determine the presence of autoantibodies as
previously described [2,3,5,19]. Ten microlitres of sera were mixed
with 2 mg of protein A Sepharose beads (Sigma, St Louis, MO, USA)
in immunoprecipitation (IPP) buffer (10 mM Tris-HCl, pH 8.0,
500 mM NaCl, 0.1% v/v Igepal) at room temperature for 30 min.
Beads were washed in IPP buffer prior to the addition of 120 ml of
[35S] methionine-labelled K562 cell extract in IPP buffer. Samples
were mixed at 4 C for 2 h. Beads were washed in IPP buffer and
Tris-buffered saline (10 mM Tris-HCl, pH 7.4, 150 mM NaCl) before
being re-suspended in 50 ml of SDS sample buffer (Sigma). After
heating, proteins were fractionated by SDS-PAGE, enhanced, ﬁxed
and dried. Labelled proteins were analysed by autoradiography.
Sera known to contain the following autoantibodies were always
included as controls; normal serum, anti-Jo-1, anti-U1RNP, anti-
RNAPII, anti-PmScl, anti- Ro 60, anti-La, anti-Mi2, anti-Ku, anti-
SAE anti-RNAPI/III, anti-U3RNP anti-p155/140, anti-PL7, anti-PL12,
anti- Zo, anti-SRP, anti-Scl-70, and anti-NXP2.
As immunoprecipitation is unable to identify all myositis spe-
ciﬁc and associated autoantibodies of interest additional testing
was performed as follows: In patients with a 140 kDa band on
immunoprecipitation speciﬁcity for anti-NXP2 or anti-MDA5 was
determined by ELISA as previously published [2,3]. Where small
nuclear ribonuclear proteins were seen on immunoprecipitation
the presence of anti-U1RNP and/or anti-Sm was determined by
Western blotting of a Hep2 cell extract as previously described [20].
With the exception of the JIA patient cohort, where insufﬁcient
serum was available, the presence of anti-HMGCR was determined
in all patient and control samples by ELISA using recombinant an-
tigen, as previously described [21]. See Fig. 1 for an overview of the
autoantibody detection process.
2.7. Statistical analysis
Statistical analysis was performed using R [22]. For independent
analyses, chi-squared tests were used to assess potentialPlease cite this article in press as: S.L. Tansley, et al., Autoantibodies in ju
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tients classiﬁed as PM or not PM. Generalised linear models were
used to determine the relationship between key disease features
and autoantibody subgroups using logistic regression for binary
variables and Poisson regression for categories of continuous vari-
ables. In this way the clinical features of patients within an auto-
antibody deﬁned subgroup were compared to the remainder of the
cohort allowing adjustment for variables including other autoan-
tibody subgroups, age at disease onset and disease duration. The
selection of variables included in the ﬁnal models was made based
on Akaike information criterion by considering all possible subsets
of variables [23].
3. Results
3.1. Myositis speciﬁc autoantibodies are exclusively found in those
patients with myositis
Demographic data for the different cohorts are shown in Table 1.
Myositis speciﬁc or associated autoantibodies were identiﬁed in
225 (59%) of patients in the myositis cohort but in none of the
patients of the other disease groups (318 JIA, 21 JSLE, 27 muscular
dystrophy) or healthy children, with the exception of theMAA anti-
U1RNP which was found in 38% of JSLE patients. One JDM patient
was found to have more than one autoantibody; anti-TIF1g and
anti-U1RNP and this case was excluded from further phenotype
analyses. The myositis cohort contained 8 patients identiﬁed as
‘other idiopathic inﬂammatory myopathy’ comprising patients
with focal myositis, viral myositis and CANDLE syndrome; it is
noteworthy that none of this group had a detectable autoantibody.
Some situations can make the diagnosis of juvenile myositis
more challenging. Ten patients (2.6%) were classiﬁed polymyositis
or polymyositis with overlap Connective Tissue Disease (CTD), and
did not have a rash at presentation. A further 89 (25%) had a lowest
ever recorded CMAS 48, corresponding to no clinically detectable
weakness [24]. In both groups the prevalence of an autoantibody
was 80% and 54% respectively and not signiﬁcantly different from
the remainder of the cohort (p ¼ 0.33 and 0.27 respectively),
emphasising that analysis for autoantibodies may be highly infor-
mative in these diagnostically challenging cases.
3.2. Myositis speciﬁc and associated autoantibody prevalence
The prevalence of autoantibody subgroups in the juvenile
myositis cohort is shown in Fig. 2. Autoantibody prevalence was
inﬂuenced by age at disease onset, see below and Fig. 3. Patients
with anti-HMGCR were more likely to describe themselves as
‘other’ ethnicity (OR 2.78 (1.26e6.15), p ¼ 0.011), (options included
White, Black, Indian subcontinent and other), but no other associ-
ations between autoantibody and ethnic background were
identiﬁed.
3.3. Autoantibody associated disease features
Using generalised linear regression analyses, as described above,
we investigated associations between key muscular and extra-
muscular disease features and autoantibody subgroups. Table 2A
summaries the disease phenotype associated with each autoanti-
body in terms of key clinical features. Table 2B summarises the
disease severity of autoantibody associated disease groups in terms
of muscle strength, physician global assessment score and the
likelihood of receiving second-line therapies. Only two deaths are
known to have occurred in the JDCBS cohort as a whole and no
patient has been reported to have presented with or subsequently
developed a malignancy, as such mortality and malignancy werevenile-onset myositis: Their diagnostic value and associated clinical
dx.doi.org/10.1016/j.jaut.2017.06.007
Fig. 1. A ﬂow chart describing the autoantibody detection process. a. Anti-HMGCR testing by ELISA was not performed on samples from the JIA cohort due to insufﬁcient available
serum.
Table 1
Demographic and autoantibody data for the 793 children included in this study.
Cohort (n) Median age at onset (IQR) Female n (%) Autoantibody identiﬁable (%)
Total MSA MAA
Juvenile myositis (379)a 6.8 (3.9e10.1) 267a (70) 225 (59) 185 (49) 40 (11)
JDM (316) 6.3 (3.7e10.0) 218 (69) 187 (59) 174 (55) 13 (4)
JPM (6) 12.0 (11.4e13.5) 4 (67) 6 (100) 5 (83) 1 (17)
Overlap CTD or MCTD (49) 9.0 (6.7e11.7) 40 (83) 31 (63) 6 (12) 25 (51)
Other IIMb (8) 8.9 (3.1e12.8) 7 (58) 0 0 0
JIA (318c) 6.3 (2.8e10.4) 203 (63) 0 0 0
JSLE (21) 16.3 (14.4e16.7) 17 (81) 8 (38) 0 8 (38)d
Muscular dystrophye (27) 9 (7.5e14) 2 (7.4) 0 0 0
Healthy controls (48) 13.4 (10.9e14.8) 25 (52) 0 0 0
IQR; interquartile range MSA; myositis speciﬁc autoantibody MAA; myositis associated autoantibody JDM0 juvenile dermatomyositis JPM; juvenile polymyositis CTD; con-
nective tissue disease MCTD; mixed connective tissue disease JIA; juvenile idiopathic arthritis JSLE; juvenile-onset systemic lupus erythematosus.
a 380 patients screened and one patient with anti-TIF1g and anti-U1RNP excluded from further analysis.
b 2 focal myositis, 2 brothers with CANDLE syndrome, 2 viral/post-infective myositis, 1 C1q deﬁciency infantile lupus, 1 ‘inﬂammatory myopathy and panniculitis’.
c 16 systemic, 164 oligoarticular, 8 rheumatoid factor positive polyarthritis, 78 rheumatoid factor negative polyarthritis, 22 psoriatic arthritis, 15 enthesitis related arthritis,
7 undifferentiated, 8 missing data.
d All anti-U1RNP.
e 20 Duchenne muscular dystrophy, 5 Becker muscular dystrophy and 2 Limb Girdle muscle dystrophy type 2D.
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3.4.1. Anti-transcription intermediary factor 1 g (anti-TIF1 g, anti-
p155/140)
Anti-TIf1g is the most prevalent autoantibody in the myositisPlease cite this article in press as: S.L. Tansley, et al., Autoantibodies in ju
phenotype in a large UK cohort, Journal of Autoimmunity (2017), http://cohort; identiﬁable in 18% of patients. It was associated with
cutaneous ulceration (OR 3.08 (1.65e5.73), p < 0.001) and greater
muscle weakness as determined by CMAS (OR 1.15 (1.07e1.24),
p < 0.001). These patients were more likely to have received
treatment with a biologic drug (OR 2.37 (1.30e4.31), p ¼ 0.005)
and/or intravenous cyclophosphamide (OR 2.09 (1.17e3.72),
p ¼ 0.013).venile-onset myositis: Their diagnostic value and associated clinical
dx.doi.org/10.1016/j.jaut.2017.06.007
Fig. 2. The prevalence of myositis speciﬁc and associated autoantibodies in the juvenile-onset myositis cohort (n ¼ 379). An autoantibody was identiﬁed in 225 patients (59%). The
most common autoantibody subgroups were anti-TIF1g (18%), anti-NXP2 (15%) and anti-MDA5 (6%). Alternative autoantibodies were collectively identiﬁed in the remaining 20%.
Nil identiﬁed; No known autoantibody identiﬁed using the techniques described (42% of this group have unidentiﬁed bands visible on immunoprecipitation). Other; 1 each of anti-
Ro60, anti-Ku, anti-Scl70, anti-Mitochondrial antibody and anti-U3RNP. Anti-synthetase; 3 patients with anti-Jo-1, 2 anti-PL12 and 1 anti-PL7.
Fig. 3. The median age at disease onset for patients with juvenile-onset myositis was 6.9 years. As illustrated, the median age at disease onset varied between autoantibody
subgroups. Anti-U1RNP, anti-synthetase and ‘other’ myositis associated autoantibodies were all more likely to be identiﬁed in older patients. ASS; anti-synthetase (3 patients with
anti-Jo-1, 2 anti-PL12 and 1 anti-PL7) other; 1 anti-Ku, 1 anti-SCl70, 1 anti-Ro60, 1 anti-U3RNP, 1 anti-Mitochondrial antibody. None identiﬁed; No known autoantibody identiﬁed
using the techniques described (42% of this group have unidentiﬁed bands visible on immunoprecipitation).
S.L. Tansley et al. / Journal of Autoimmunity xxx (2017) 1e10 53.4.2. Anti-nuclear matrix protein 2 (anti-NXP2, anti-MJ, anti-
p140)
Anti-NXP2 was present in 15% of myositis patients and was
associated with a younger age at disease onset (OR 0.91
(0.84e0.98), p ¼ 0.012). It was also associated with greater musclePlease cite this article in press as: S.L. Tansley, et al., Autoantibodies in ju
phenotype in a large UK cohort, Journal of Autoimmunity (2017), http://weakness (OR 1.44 (1.35e1.55), p < 0.001). We have previously
published that this Ab is associatedwith risk of calcinosis [2]. In this
larger cohort the association between anti-NXP2 and the devel-
opment of calcinosis bordered on signiﬁcance (OR 1.82 (0.99e3.36),
p ¼ 0.055).venile-onset myositis: Their diagnostic value and associated clinical
dx.doi.org/10.1016/j.jaut.2017.06.007
Table 2A
The association of key clinical disease features with autoantibody subgroups.
Classiﬁed as PM (%) Dysphagiaa (%) Calcinosisa (%) Ulcerationa (%) Oedemaa (%) Lipoatrophya (%) Arthritisa (%)
Total cohort (n ¼ 379)b 10 (2.6) 96 (26) 120 (32) 76 (20) 155 (41) 57 (15) 148 (40)
Anti-TIF1g
(n ¼ 68)
0 18 (26) 25 (37) 23 (34)*** 32 (47) 13 (19) 26 (38)
Anti-NXP2
(n ¼ 59)
0 17 (29) 25 (43) 8 (14) 26 (44) 9 (16) 20 (34)
Anti-MDA5
(n ¼ 23)
0 7 (30) 7 (27) 11 (50)*** 10 (43) 3 (13) 15 (65)*
Anti-PmScl
(n ¼ 20)
0 5 (25) 11 (55)* 4 (20) 5 (25) 6 (30)* 11 (44)
Anti- Mi2
(n ¼ 15)
0 7 (47)* 4 (27) 0 11 (73)* 2 (13) 6 (40)
Anti-U1RNP
(n ¼ 14)
3 (21)*** 6 (43) 1 (8) 2 (14) 2 (14) 2 (14) 7 (50)
Anti-SRP
(n ¼ 7)
2 (29)*** 3 (43) 1 (14) 4 (50)** 5 (71) 1 (13) 2 (29)
Anti-synthetasec
(n ¼ 6)
0 0 1 (17) 2 (33) 3 (50) 2 (33)* 2 (33)
Anti-HMGCR
(n ¼ 4)
2 (50)*** 3 (75)* 0 0 0 0 0
Anti-SAE
(n ¼ 3)
0 0 1 (33) 1 (33) 1 (33) 1 (33) 2 (66)
Otherd
(n ¼ 5)
1 (20)** 3 (60) 1 (20) 2 (50) 1 (20) 2 (50) 3 (60)
Nil identiﬁede
(n ¼ 155)
2 (1) 27 (17) 44 (28) 19 (12) 59 (38) 16 (10) 54 (35)
Statistically signiﬁcant associations are highlighted in bold.
*P < 0.05, **P < 0.01, ***P < 0.001, PM; polymyositis.
a Data available for 374 patients.
b Including 8 patients with other idiopathic inﬂammatory myopathy.
c 3 patients anti-Jo-1, 2 patients anti-PL12 and 1 patient anti-PL7.
d 1 anti-Ku, 1 anti-Scl70, 1 anti-Ro60, 1 anti-U3RNP, 1 anti-mitochondrial antibody.
e No known autoantibody identiﬁed using the techniques described (42% of this group have unidentiﬁed bands visible on immunoprecipitation).
Table 2B
The association of key clinical outcome measures with autoantibody subgroups.
Lowest ever CMASa median (IQR) Highest ever PGAb median (IQR) Ever received biologic drug (%) Ever received IV cyclophosphamide (%)
Total cohort (n ¼ 379)c 40 (24.5e47.5) 4 (2.2e7.0) 77 (20) 89 (23)
Anti-TIF1g
(n ¼ 68)
40 (25e47)** 5.2 (2.6e7.6) 23 (34)** 25 (37)*
Anti-NXP2
(n ¼ 59)
29.5 (16e43)*** 4.6 (2.7e6.9) 11 (19) 10 (17)
Anti-MDA5
(n ¼ 23)
45 (38e52)*** 4.1 (3.1e6.7) 1 (4) 6 (26)
Anti-PmScl
(n ¼ 20)
45.5 (22e49) 3 (1.5e6.9) 3 (15) 5 (25)
Anti- Mi2
(n ¼ 15)
29 (15e38)*** 4.8 (2.45e7) 1 (7) 3 (20)
Anti-U1RNP
(n ¼ 14)
46.5 (42e49)*** 3.4 (1e5.2) 2 (14) 1 (7)
Anti-SRP
(n ¼ 7)
26 (9.8e42)*** 6.6 (3.5e6.9) 2 (29) 2 (29)
Anti-synthetased
(n ¼ 6)
44.5 (41e48) 3.3 (2.4e5.5) 1 (17) 2 (33)
Anti-HMGCR
(n ¼ 4)
15 (1e30)*** 6.6 (4.4e8.6) 4 (100) 2 (50)
Anti-SAE
(n ¼ 3)
39 (23e47) 3.5 (2e7) 0 0
Othere
(n ¼ 5)
40 (25e47)** 4.1 (2.3e7) 2 (40) 1 (20)
Nil identiﬁedf
(n ¼ 155)
43 (27e48) 3.2 (2.0e6.0) 28 (18) 32 (21)
Statistically signiﬁcant associations are highlighted in bold.
*P < 0.05, **P < 0.01, ***P < 0.001, PM; polymyositis.
CMAS; Childhood Myositis Assessment Score, PGA; Physician Global Assessment of disease activity.
a Data available for 355 patients.
b Data available for 370 patients.
c Including 8 patients with other idiopathic inﬂammatory myopathy.
d 3 patients anti-Jo-1, 2 patients anti-PL12 and 1 patient anti-PL7.
e 1 anti-Ku, 1 anti-Scl70, 1 anti-Ro60, 1 anti-U3RNP, 1 anti-mitochondrial antibody.
f No known autoantibody identiﬁed using the techniques described (42% of this group have unidentiﬁed bands visible on immunoprecipitation).
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MDA5, anti-CADM 140)
Anti-MDA5 is the third most common autoantibody in the
myositis cohort andwas identiﬁed in 6% of patients. It was inversely
associated with muscle weakness determined by CMAS (OR 0.57
(0.49e0.66), p < 0.001), conﬁrming our previous observation that
patients with anti-MDA5 are less likely to be weak [3]. Anti-MDA5
was also associated with cutaneous ulceration (OR 5.74
(2.32e14.17), p < 0.001), and arthritis (OR 2.81 (1.140e6.94),
p ¼ 0.023). Data on the presence or absence of interstitial lung
disease in the cohort was incomplete and not included in regres-
sion analyses however, using the same cohort we have previously
shown that 19% of those with anti-MDA5 developed interstitial
lung disease and none rapidly progressive interstitial lung disease
[3].
3.4.4. Anti-Mi2
Anti-Mi2 was identiﬁed in 4% of myositis patients and was
associated with greater muscle weakness (OR 1.70 (1.53e1.89),
p < 0.001) dysphagia (OR 3.09 (1.05e9.06), p ¼ 0.040), and oedema
(OR 4.10 (1.26e13.30), p ¼ 0.019) than other patients in the cohort.
3.4.5. Anti-signal recognition peptide (anti-SRP)
Anti-SRP was rare and found in just 2% of myositis patients.
These patients were more likely to be classiﬁed as polymyositis (OR
66.6 (7.76e571.61), p < 0.001). Anti-SRP was associated with
greater muscle weakness (OR 1.15 (1.07e1.24), p < 0.001) and
cutaneous ulceration (OR 7.65 (1.65e35.54), p ¼ 0.009). No statis-
tically signiﬁcant associations were seen with treatment received
but a greater proportion of these patients did receive both intra-
venous cyclophosphamide and biologic drugs, see Fig. 4.
3.4.6. Anti-tRNA synthetase
An anti-tRNA synthetase autoantibody was identiﬁed in 2% of
myositis patients who were also more likely to be older at disease
onset (OR 1.38 (1.08e1.76), p ¼ 0.009). Anti-tRNA synthetaseFig. 4. The proportion of myositis patients within each autoantibody deﬁned subgroup who
drug (light grey) is shown.
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(OR 0.77 (0.61e0.98), p ¼ 0.041), suggesting patients are less likely
to be weak. They were also associated with the development of
lipoatrophy (OR 7.06 (1.13e43.96), p ¼ 0.036). Three patients had
anti-Jo-1 autoantibodies, two anti-PL12 and one anti-PL7. Those
patients with anti-PL12 and anti-PL7 developed interstitial lung
disease but this did not occur in the patients with anti-Jo-1.
3.4.7. Anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
(anti-HMGCR)
Anti-HMGCRwas found in just four patients (1%). These patients
were more likely to be classiﬁed as polymyositis (OR 165.50
(15.06e1840.69), p < 0.001), had greater muscle weakness (OR 2.33
(1.97e2.76), p < 0.001) and suffer from dysphagia (OR 10.48
(1.05e104.91), p ¼ 0.046). Whilst no statistically signiﬁcant asso-
ciation was seen with treatment received it is noteworthy that all
four patients ultimately received biologic treatment and 50% IV
cyclophosphamide, see Fig. 4.
3.4.8. Anti-small ubiquitin-like modiﬁer activating enzyme (anti-
SAE)
Only three patients had anti-SAE autoantibodies. No speciﬁc
phenotype associations were identiﬁed. In keeping with previous
descriptions of the anti-SAE associated disease [25]two patients
presented with JDM rash with very little or no muscle involvement
but subsequently developed weakness and raised muscle enzymes.
In both of these patients skin disease has been a persistent problem.
In contrast the third patient presented following a seven month
history of myalgia and weakness with no rash. Myositis was diag-
nosed on the basis of raised muscle enzymes plus consistent MRI
and muscle biopsy ﬁndings. This patient developed typical cuta-
neous features of JDM two years later.
3.4.9. Myositis associated autoantibodies
3.4.9.1. Anti-polymyositis scleroderma (anti-PmScl). Anti-PmScl was
identiﬁed in 20 (5%) of myositis patients. No patient was classiﬁedreceived treatment with intravenous cyclophosphamide (dark grey) and/or a biologic
venile-onset myositis: Their diagnostic value and associated clinical
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as dermatomyositis overlap and, in keeping with the classic
description of this autoantibody, nine patients (45%) were classiﬁed
as overlap with scleroderma. The remaining 11 patients were
described as dermatomyositis (ﬁve patients), mixed connective
tissue disease (four patients), dermatomyositis polyarthritis over-
lap (one patient) or dermatomyositis lupus overlap (one patient). In
addition to overlap disease anti-PmScl were also associated with
the development of calcinosis (OR 3.31 (1.29e8.52), p ¼ 0.013) and
lipoatrophy (OR 3.08 (1.09e8.77), p ¼ 0.035).
3.4.9.2. Anti-U1 ribonucleoprotein (anti-U1RNP). Anti-U1RNP were
identiﬁed in 14 (4%) of myositis patients and were associated with
an older age at disease onset (OR 1.19 (1.04e1.36), p ¼ 0.011) and
polymyositis or polymyositis overlap (OR 45.4 (6.88e299.79),
p < 0.001). Patients were less likely to have a lower CMAS score (OR
0.54 (0.44e0.66), p < 0.001) suggesting patients are likely to be less
weak. Seven (50%) of myositis patients were classiﬁed as having
overlap disease or mixed connective tissue disease. Anti U1RNP
was also detected in the JSLE patient cohort, conﬁrming previous
reports [26]. Phenotypic data was not examined for those patients
with JSLE.
3.4.9.3. Other autoantibodies. ‘Other’ autoantibodies identiﬁed
were anti-Ku, anti-Scl70, anti-Ro60, anti-U3RNP and anti-
mitochondrial antibody. Collectively they were more likely to be
identiﬁed in older patients (OR 1.46 (1.12e1.90), p ¼ 0.005) and
were associatedwith polymyositis or polymyositis overlap (OR 33.3
(2.58e429.81), p ¼ 0.007).
3.4.9.4. No identiﬁable autoantibodies. No clinical associations
were identiﬁed with the absence of a detectable autoantibody.
4. Discussion
Juvenile myositis is a very rare disease and our large study
makes a signiﬁcant contribution to the available evidence on
autoantibody associated disease phenotype. The study is also
unique by the inclusion of several large non-myositis juvenile
control groups tested for MSA/MAA, using the same methodology,
in parallel with myositis patients. Consistent with previous studies
the MAA anti-U1RNP was common in the group with JSLE [26], in
addition to older patients with myositis-overlap disorders. In
contrast MSAwere exclusively found in juvenile-onset myositis and
accordingly were 100% speciﬁc and 49% sensitive for identifying
juvenile patients with myositis. The speciﬁcity is far superior to
anti-nuclear antibodies which, whilst identiﬁable in over 70% of
juvenile myositis patients [27], were also found in nearly 60% of the
JIA patients and 90% of the JSLE patients [27]. Therefore, the iden-
tiﬁcation of a MSA should be considered highly suggestive of the
presence of myositis or an associated overlap disorder.
As expected in patients with juvenile-onset myositis the vast
majority had dermatomyositis and the absence of cutaneous dis-
easewas rare. Those patients with polymyositis had either anti-SRP,
anti-HMGCR, anti-U1RNP or ‘other’ MAA. This is in stark contrast to
adult patients where anti-synthetase autoantibodies predominate
and suggests that adult and juvenile-onset polymyositis are likely
to present very differently [28]. This is important to recognise as the
differential diagnosis of muscle weakness is wide and particularly
for those children with anti-SRP and anti-HMGCR who often pre-
sent with profound weakness, very elevated muscle enzymes and
have a slow/poor response to treatment, the absence of a typical
dermatomyositis rash can prompt ongoing investigation for other
muscle disorders [29,30].Please cite this article in press as: S.L. Tansley, et al., Autoantibodies in ju
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hampered the development of good quality clinical trials and as
reported in a Cochrane and other systematic literature reviews the
evidence base for treatment remains very limited [31e33]. Despite
limited evidence standard treatment for JIIM in the UK consists of
immunosuppression with corticosteroids and methotrexate, a
treatment regime which has recently been conﬁrmed by a large
international trial [2e16]. It is interesting to note that patients with
some autoantibodies are more likely to receive additional ‘aggres-
sive’ treatment with IV cyclophosphamide and/or biologic drugs,
suggesting treatment resistance, severe disease or both. A signiﬁ-
cant association was seen between these more powerful treat-
ments and anti-TIF1g, the most common autoantibody in our
cohort. Patients with anti-HMGCR, anti-SRP and anti-synthetase
autoantibodies also received one or other of these treatments
more often but it is likely this study was underpowered to
demonstrate a signiﬁcant relationship with these rarer autoanti-
body subgroups. While we acknowledge that treating physicians
may have had some knowledge of autoantibody status through
routine diagnostic testing this is typically limited in the UK, and
traditional autoantibodies detected via standard methods form a
very small proportion of our juvenile cohort. Autoantibody testing
for this study was performed for research purposes only, on stored
serum samples, in a designated university laboratory, often many
years after diagnosis. Furthermore, the results were not fed back to
the treating physician and it is therefore unlikely that autoantibody
status per se could have inﬂuenced treatment choice.
Interestingly, it is not always those autoantibody categories
associated with features of severe disease, for example greater
muscle weakness as determined by CMAS, dysphagia and oedema
in the case of anti-Mi2, and greater muscle weakness with anti-
NXP2 that have a greater proportion of patients receiving aggres-
sive therapy, suggesting some subgroups may be more treatment
responsive. In the adult literature there is emerging evidence of a
differential response to B-cell depletion based on autoantibody
subgroup, suggesting that autoantibody subgroup does inﬂuence
treatment response [34,35]. To date however very few randomised
controlled trials in adult or paediatric patients have determined
autoantibody status or adjusted for this in their analyses [31]. Our
results suggest that adjusting for autoantibody status will be
important in future therapeutic clinical trials to prevent con-
founding. We know that early treatment is crucial for good out-
comes in juvenile myositis and therefore selecting a successful
treatment strategy from the outset is critical [9e12]. In the future
autoantibody testing may facilitate the earlier identiﬁcation of
those patients ultimately requiring a more aggressive treatment
approach.
A signiﬁcant strength of the study is the use of immunopre-
cipitation to determine autoantibody status, in both myositis and
controls, as the sensitivity and speciﬁcity of other commercially
available assays has yet to be validated and may be prone to false
positives [36,37]. We have shown for the ﬁrst time the absence of
MSA in patients with JIA or JSLE and our results support previous
studies suggesting the absence of MSA in patients with genetic
muscle diseases [13]. In the future a similar comparison with pa-
tients with other dermatological diagnoses such as psoriasis would
also be valuable since some children with JDM who present with
mainly rash maybe wrongly diagnosed with psoriasis early in dis-
ease. Limitations of our study include a lack of prospectively
collected data on interstitial lung disease and mortality. Informa-
tion on interstitial lung disease is however available for those pa-
tients with anti-MDA5 and anti-synthetase autoantibodies where
associations have previously been described. Only two deaths are
known to have occurred in the patients studied.venile-onset myositis: Their diagnostic value and associated clinical
dx.doi.org/10.1016/j.jaut.2017.06.007
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Autoantibodies can be identiﬁed in themajority of childrenwith
juvenile-onset myositis, and MSA are exclusively found in those
with myositis. The presence of an MSA should suggest a diagnosis
of myositis and their association with clinically important disease
features makes them useful prognostic biomarkers. There is evi-
dence of an existing differential treatment approach for some
autoantibody subgroups which warrants further investigation and
has important implications for the design of future clinical trials.
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